AAIC 2025 Abstract·9 JanPlasma proteomic analysis of a biomarker‐defined subpopulation in the SHINE Ph2 trial to identify molecular correlates to the favorable decrease in the neuroinflammatory marker GFAP with zervimesine in Alzheimer's disease participantsTrial in peopleInterventionsPaper
AAIC 2025 Abstract·26 DecExploratory CSF proteomic analysis of a pre‐specified pTau217 subgroup from the SHINE clinical trial identifies biomarkers correlated with cognitive improvement in Alzheimer’s disease patients treated with zervimesineTrial in peopleInterventionsPaper